AVE0991, the non-peptidic agonist of Mas, could blunt portal hypertension due to massive hepatic vasodilation in TGR(mREN2)27 rats, in either uninjured or cirrhotic (BDL, CCl4) models. Here, MAS1 is linked to liver disorder.